EvaluatePharma has totted up the figures for R&D spend and costs for biopharmas, and the figures are huge.

Akcea Therapeutics is closing in on an IPO expected to gross in the region of $125 million.

Gamida Cell has upped its financing by $40 million in its latest funding round to prep for final work on a late-stage stem cell blood cancer therapy.

Neil Woodford has invested in the Big Pharma-backed Dementia Discovery Fund.

An Ernst & Young report shows a mixed bag across the whole sector.

A new funding round for Checkmate Pharma will fund additional trials of immuno-oncology drug CMP-001.

Ocugen has raised $7.5 million in a series B round as it fixes its sights on advancing a trio of eye disease treatments into clinical trials.

Novartis and Verily have helped Medicxi raise $300 million to invest in late-stage drug developers.

LifeArc has set up a seed fund to invest in early preclinical projects that are overlooked because of the high risk of failure at that stage of R&D.

Life sciences VC Flagship Pioneering has been attracting some big names to its top management and shows no signs of letting up.

Venture Capital